These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 33993810)

  • 1. Avoiding hindsight in non-obviousness determination: case law review of pharmaceutical patents and guidance from the KSR v Teleflex decision.
    Dhulap S; Kulkarni MG
    Expert Opin Ther Pat; 2021 Oct; 31(10):951-963. PubMed ID: 33993810
    [No Abstract]   [Full Text] [Related]  

  • 2. Obviousness, hindsight and perspective: the impact of KSR v. Teleflex on biotech and pharmaceutical patents.
    Teitelbaum R; Cohen M
    Nat Biotechnol; 2007 Oct; 25(10):1105-6. PubMed ID: 17921990
    [No Abstract]   [Full Text] [Related]  

  • 3. Strategies for strengthening patent protection of pharmaceutical inventions in light of federal court decisions.
    Pillai X; Kinney WA
    Curr Top Med Chem; 2010; 10(18):1929-36. PubMed ID: 20615184
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nonobviousness of pharmaceutical inventions: implications for patent prosecution and litigation.
    Dhulap S; Kulkarni M
    Pharm Pat Anal; 2019 Jul; 8(4):91-107. PubMed ID: 31414965
    [TBL] [Abstract][Full Text] [Related]  

  • 5. KSR v. Teleflex. Part 1: Impact of U.S Supreme Court Patent Law on Canadian intellectual property and regulatory rights landscape.
    Bouchard RA
    Health Law J; 2007; 15():221-46. PubMed ID: 19702184
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmaceutical patent life-cycle management after KSR v. Teleflex.
    Furrow ME
    Food Drug Law J; 2008; 63(1):275-320. PubMed ID: 18561462
    [No Abstract]   [Full Text] [Related]  

  • 7. Pharmaceutical patent law: the Canadian perspective.
    Aumand L; Norman J
    Pharm Pat Anal; 2016 Jul; 5(4):271-9. PubMed ID: 27346187
    [TBL] [Abstract][Full Text] [Related]  

  • 8. KSR Int'l Co. v. Teleflex, Inc.: no obvious changes for the biotechnology market.
    Hinneschiedt CH
    Yale J Biol Med; 2007 Dec; 80(4):153-7. PubMed ID: 18449391
    [TBL] [Abstract][Full Text] [Related]  

  • 9. What is your reasonable expectation of success in obtaining pharmaceutical or biotechnology patents having nonobvious claimed inventions that the courts will uphold? An overview of obviousness court decisions.
    Pereira DJ; Kunin SG
    Cold Spring Harb Perspect Med; 2014 Dec; 5(4):. PubMed ID: 25475106
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of the factors that result in obviousness rulings for biotech patents: an updated analysis of the US Federal Circuit decisions after KSR.
    Lin F; Wang SJ
    Hum Vaccin Immunother; 2013 Nov; 9(11):2490-5. PubMed ID: 23899509
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 'Reference composition' not 'lead compound': recent developments in case law for obviousness of pharmaceutical composition claims.
    Highlander SL; Voges MH
    Pharm Pat Anal; 2012 Sep; 1(4):385-92. PubMed ID: 24236877
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Deuterated drugs; updates and obviousness analysis.
    Timmins GS
    Expert Opin Ther Pat; 2017 Dec; 27(12):1353-1361. PubMed ID: 28885861
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inventions in biotechnology and the assessment of obviousness.
    Finney K
    Australas Biotechnol; 1994; 4(5):280-3. PubMed ID: 7765674
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intellectual property. Drug patents at the Supreme Court.
    Hemphill CS; Sampat B
    Science; 2013 Mar; 339(6126):1386-7. PubMed ID: 23520096
    [No Abstract]   [Full Text] [Related]  

  • 15. KSR v. Teleflex. Part 2: Impact of U.S Supreme Court Patent Law on Canadian and global systems-based innovation ecologies.
    Bouchard RA
    Health Law J; 2007; 15():247-94. PubMed ID: 19702185
    [No Abstract]   [Full Text] [Related]  

  • 16. The strategy of enantiomer patents of drugs.
    Agranat I; Wainschtein SR
    Drug Discov Today; 2010 Mar; 15(5-6):163-70. PubMed ID: 20116449
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patent law protection of inventions in medicine and pharmaceutical industry.
    Miladinović Z; Varga S; Radojković M
    Vojnosanit Pregl; 2013 Jun; 70(6):600-5. PubMed ID: 23885528
    [No Abstract]   [Full Text] [Related]  

  • 18. Generics still unable to resolve ANDA patent issues by declaratory judgment, but is a supreme court resolution on the way?
    Eccleston LE
    Health Care Law Mon; 2006 Dec; ():3-5. PubMed ID: 17236678
    [No Abstract]   [Full Text] [Related]  

  • 19. The obviousness rejection as a barrier to vaccine patent prosecution.
    Wang SJ
    Hum Vaccin; 2011 Apr; 7(4):474-6. PubMed ID: 21808149
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmaceutical patent law: expert perspectives from around the globe.
    Komatani TS
    Pharm Pat Anal; 2016 Jul; 5(4):195-7. PubMed ID: 27409277
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.